Form 4: Alzamend Neuro Director William Horne Reports Stock Option Exercise and Open Market Purchase

Director William Horne exercised stock options and purchased shares of Alzamend Neuro (ALZN) common stock on March 18, 2025.

Summary

• On March 18, 2025, William B. Horne, a director of Alzamend Neuro, Inc. (ALZN), exercised stock options to acquire 10,000 shares of common stock at a price of $0.06 per share.
• Horne also purchased 5,000 shares of ALZN common stock in the open market at a weighted average price of $0.9703 per share, with prices ranging from $0.9693 to $0.9742.
• Following these transactions, Horne beneficially owns 21,666 shares of ALZN common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

Alzamend Neuro, ALZN, William Horne, Director, Stock Options, Open Market Purchase, Beneficial Ownership, SEC Form 4